Cytovance Biologics, Inc. has entered a development and manufacturing agreement with Selexys Pharmaceuticals for SELK2, an investigational humanized monoclonal antibody for the potential treatment of Crohn’s Disease and Multiple Myeloma. Cytovance will provide process development, scale up and cGMP manufacturing services of SELK2 to support a Phase I trial.   “With this agreement, Selexys continues its longstanding relationship with Cytovance,” said Dr. Scott Rollins, president...